The journey of tumor-infiltrating lymphocytes as a biomarker in breast cancer: clinical utility in an era of checkpoint inhibition

High tumor mutation burden fails to predict immune checkpoint blockade response across all cancer types

(2021) D.J. McGrail et al.   ANNALS OF ONCOLOGY

Palbociclib for Residual High-Risk Invasive HR-Positive and HER2-Negative Early Breast Cancer—The Penelope-B Trial

(2021) Sibylle Loibl et al.   JOURNAL OF CLINICAL ONCOLOGY

The 2019 WHO classification of tumours of the breast

(2020) Puay Hoon Tan et al.   HISTOPATHOLOGY

The path to a better biomarker: application of a risk management framework for the implementation of PD‐L1 and TILs as immuno‐oncology biomarkers into breast cancer clinical trials and daily practice

(2020) Paula I Gonzalez‐Ericsson et al.   JOURNAL OF PATHOLOGY

Tissue-resident memory T cells in breast cancer control and immunotherapy responses

(2020) Ann Byrne et al.   Nature Reviews Clinical Oncology

Pembrolizumab for Early Triple-Negative Breast Cancer

(2020) Peter Schmid et al.   NEW ENGLAND JOURNAL OF MEDICINE

Expanding the Role for Immunotherapy in Triple-Negative Breast Cancer

(2020) Peter Savas et al.   CANCER CELL

KEYNOTE-355: Randomized, double-blind, phase III study of pembrolizumab + chemotherapy versus placebo + chemotherapy for previously untreated locally recurrent inoperable or metastatic triple-negative breast cancer.

(2020) Javier Cortes et al.   JOURNAL OF CLINICAL ONCOLOGY

Pitfalls in assessing stromal tumor infiltrating lymphocytes (sTILs) in breast cancer

(2020) Zuzana Kos et al.   npj Breast Cancer

159O Prognostic value of tumour infiltrating lymphocytes in young triple negative breast cancer patients who did not receive adjuvant systemic treatment; by the PARADIGM study group

(2020) V.M.T. De Jong et al.   ANNALS OF ONCOLOGY

Trastuzumab emtansine plus atezolizumab versus trastuzumab emtansine plus placebo in previously treated, HER2-positive advanced breast cancer (KATE2): a phase 2, multicentre, randomised, double-blind trial

(2020) Leisha A Emens et al.   LANCET ONCOLOGY

How current assay approval policies are leading to unintended imprecision medicine

(2020) Roberto Salgado et al.   LANCET ONCOLOGY

Association of tumor-infiltrating lymphocytes with distant disease-free survival in the ShortHER randomized adjuvant trial for patients with early HER2+ breast cancer

(2019) M V Dieci et al.   ANNALS OF ONCOLOGY

Checkpoint Blockade Immunotherapy Induces Dynamic Changes in PD-1−CD8+ Tumor-Infiltrating T Cells

(2019) Sema Kurtulus et al.   IMMUNITY

Tumor-Infiltrating Lymphocytes and Prognosis: A Pooled Individual Patient Analysis of Early-Stage Triple-Negative Breast Cancers

(2019) Sherene Loi et al.   JOURNAL OF CLINICAL ONCOLOGY

Pembrolizumab plus trastuzumab in trastuzumab-resistant, advanced, HER2-positive breast cancer (PANACEA): a single-arm, multicentre, phase 1b–2 trial

(2019) Sherene Loi et al.   LANCET ONCOLOGY

A randomised phase II study investigating durvalumab in addition to an anthracycline taxane-based neoadjuvant therapy in early triple negative breast cancer – clinical results and biomarker analysis of GeparNuevo study

(2019) S Loibl et al.   ANNALS OF ONCOLOGY

Genomic correlates of response to adjuvant trastuzumab (H) and pertuzumab (P) in HER2+ breast cancer (BC): Biomarker analysis of the APHINITY trial.

(2019) Ian E. Krop et al.   JOURNAL OF CLINICAL ONCOLOGY

Immune induction strategies in metastatic triple-negative breast cancer to enhance the sensitivity to PD-1 blockade: the TONIC trial

(2019) Leonie Voorwerk et al.   NATURE MEDICINE

Early breast cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up†

(2019) F Cardoso et al.   ANNALS OF ONCOLOGY

Estimating the benefits of therapy for early-stage breast cancer: the St. Gallen International Consensus Guidelines for the primary therapy of early breast cancer 2019

(2019) H J Burstein et al.   ANNALS OF ONCOLOGY

Atezolizumab plus nab-paclitaxel as first-line treatment for unresectable, locally advanced or metastatic triple-negative breast cancer (IMpassion130): updated efficacy results from a randomised, double-blind, placebo-controlled, phase 3 trial

(2019) Peter Schmid et al.   LANCET ONCOLOGY

Prognostic value of tumor-infiltrating lymphocytes in patients with early-stage triple-negative breast cancers (TNBC) who did not receive adjuvant chemotherapy

(2019) J H Park et al.   ANNALS OF ONCOLOGY

Single-cell profiling of breast cancer T cells reveals a tissue-resident memory subset associated with improved prognosis

(2018) Peter Savas et al.   NATURE MEDICINE

Co-expression of CD39 and CD103 identifies tumor-reactive CD8 T cells in human solid tumors

(2018) Thomas Duhen et al.   Nature Communications

Dichotomous histopathological assessment of ductal carcinoma in situ of the breast results in substantial inter-observer concordance

(2018) Mieke Van Bockstal et al.   HISTOPATHOLOGY

Bystander CD8+ T cells are abundant and phenotypically distinct in human tumour infiltrates

(2018) Yannick Simoni et al.   NATURE

Long-term Clinical Outcomes and Biomarker Analyses of Atezolizumab Therapy for Patients With Metastatic Triple-Negative Breast Cancer

(2018) Leisha A. Emens et al.   JAMA Oncology

Pembrolizumab monotherapy for previously untreated, PD-L1-positive, metastatic triple-negative breast cancer: cohort B of the phase II KEYNOTE-086 study

(2018) S Adams et al.   ANNALS OF ONCOLOGY

Pembrolizumab monotherapy for previously treated metastatic triple-negative breast cancer: cohort A of the phase II KEYNOTE-086 study

(2018) S Adams et al.   ANNALS OF ONCOLOGY

Radiotherapy induces responses of lung cancer to CTLA-4 blockade

(2018) Silvia C. Formenti et al.   NATURE MEDICINE

Tumour-infiltrating lymphocytes in advanced HER2-positive breast cancer treated with pertuzumab or placebo in addition to trastuzumab and docetaxel: a retrospective analysis of the CLEOPATRA study

(2017) Stephen J Luen et al.   LANCET ONCOLOGY

Role of Cytotoxic Tumor-Infiltrating Lymphocytes in Predicting Outcomes in Metastatic HER2-Positive Breast Cancer

(2017) Shuzhen Liu et al.   JAMA Oncology

The prevalence and clinical relevance of tumor-infiltrating lymphocytes (TILs) in ductal carcinoma in situ of the breast

(2016) G. Pruneri et al.   ANNALS OF ONCOLOGY

Diagnostic Concordance Among Pathologists Interpreting Breast Biopsy Specimens

(2015) Joann G. Elmore et al.   JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION

Use of Archived Specimens in Evaluation of Prognostic and Predictive Biomarkers

(2009) R. M. Simon et al.   JNCI-Journal of the National Cancer Institute